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1. Introduction 
Although much has been characterized about squamous cell carcinoma of the lower female 
reproductive tract, there is limited knowledge and experience with cases demonstrating 
squamous cell carcinoma with sarcomatoid features. Sarcomatoid squamous cell carcinoma 
(SSCC) is mainly found in the upper aerodigestive tract with the larynx being the most 
common site in the head and neck region. (Otay et al., 2011) The esophagus and skin are 
other well known affected sites. In these sites, risk factors include, smoking, alcohol 
consumption, and previous irradiation of the head and neck region. (Otay et al., 2011) Risk 
factors for skin involvement include prolonged sun exposure and the effects of toxins and 
irradiation.  
True sarcomas of the lower female genital tract arising in the vulva, vagina, and cervix, are 
extremely rare. They comprise only 1-2% of vulvar cancers, 2% of vaginal cancers (Temkin 
et.al,2007), 2-3% of cervical cancers, and 3% of endometrial cancers. They tend to be 
heterogeneous, rapidly progressive, with a high rate of recurrence and distant metastasis to 
organs such as liver and lungs. For the vulva and vagina, the main sites of occurrence are 
the labium majus and upper vagina, respectively. Leiomyosarcomas are the most common 
type of sarcoma in the female genital tract where several factors have been demonstrated to 
play a role in recurrence including tumor diameter, cytologic atypia, mitotic index, and 
infiltrating margins. Although there are no specific treatment guidelines, the mainstay of 
therapy has been surgical excision followed by chemotherapy. Neoadjuvant chemotherapy 
has been used in patients who have bulky tumors in which surgical debulking had not been 
optimal. Currently, some believe that neoadjuvant chemotherapy can also be used as 
primary therapy followed by surgical debulking regardless of tumor. It is thought that this 
treatment strategy can optimize surgical excision, giving rise to less morbidity, and a longer 
disease-free interval. (Temkin et.al,2007) The role of radiation therapy has been controversial 
as some believe that sarcomas themselves are induced by a history of radiation therapy or 
exposure. Nevertheless, there have been reports of radiation lengthening the time interval to 
local recurrence.   
Sarcomatoid squamous cell carcinoma of the female genital tract has been reported in very 
small numbers. Human Papilloma Virus (HPV) has been known to be a major causal factor 
for the development of SCC. High risk subtypes of Human Papilloma Virus, 16 and 18, have 
been demonstrated in not only the squamous cell component of SSCC but also in the 
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sarcomatoid component. Making immunohistochemical assays of this cancer a hallmark to 
diagnosis to differentiate pure squamous cell carcinoma from a pure sarcoma. 
Like pure sarcomas, Sarcomatoid Squamous Cell Carcinoma has a very poor prognosis, 
short disease-free intervals, and is diagnosed at later stages of disease. Even with optimal 
treatment and follow up, SSCC recur rapidly and metastasize to regions such as the 
peritoneum, kidney, and subcutaneous tissue. Most cases of SSCC of the female genitalia 
have been reported to arise from the cervix and vulva. There are currently 16 cases of 
cervical and vulvar SSCC reported in the English literature to date. (Tae-Wook Kong et. al., 
2010 and Dong-Seok Choi et. al., 2006), with our current case of vulvar SSCC making up the 
17th case. 
SSCC of the Cervix Literature Review 
 
 
 
 
 
Table 1. SSCC of the Cervix Reported Cases in the Literature (Tae-Wook King et al, 2010) 
N/A= not available, ER= external pelvic radiation therapy, RAH= radical abdominal 
hysterectomy, CRT= chemoradiation therapy, TAH= total abdominal hysterectomy, LRH= 
laparoscopic radical hysterectomy, PD= progressive disease, RD= recurrent disease, CR= 
complete remission, DOD= dead of disease, NED= no evidence of disease 
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IF-LN= inguino-femoral lymph node metastasis, P-LN= pelvic lymph node metastasis, DFI= disease 
free interval, NA= not available, SCC= squamous cell carcinoma, NED= no evidence of disease, RV= 
radical vulvectomy, LND= lymph node dissection, CTx= chemotherapy, RTx= radiation therapy 
 
Table 2. SSCC of the Vulva Reported Cases in the Literature (D.-S. Choi et al, 2006) 
Four cases of vaginal SSCC have been reported, with our current case constituting the fifth.  
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Table 3. SSCC of the Vagina Reported Cases in the Literature (Raptis et al, 1993) 
The low volume of cases poses a dilemma in that institutional encounters of such cases are 
sporadic and as such, there are no established guidelines for diagnosis or treatment. These 
cancers have traditionally been treated and staged similar to squamous cell carcinomas of 
their respective sites using the FIGO staging system. There has been reported success in long 
term survival rates of patients who present earlier in the disease and whose tumors could be 
fully resected. These presentations are rare, as patients tend to present with long standing 
bulky tumors and with metastasis.  
2. Case report 
Two cases of sarcomatoid squamous cell carcinoma, one of the vagina and one of the vulva, 
will be utilized as illustrative examples of this rare entity.  
Case number one: 67 year old, Gravida 7 Para 6 woman status post total abdominal 
hysterectomy 13 years prior for reportedly benign fibroids, presented with profuse vaginal 
bleeding. Examination revealed a vaginal lesion which was biopsied, revealing a high-
grade, malignant sarcomatoid neoplasm with no concurrent precursor lesion, such as an in-
situ component. Pathologic assessment suggested that this was a sarcoma, specifically, a 
leiomyosarcoma, as evidence of smooth muscle differentiation was demonstrated by 
immunohistochemisty. However, with subsequent demonstration of pelvic sidewall and 
pelvic lymph node involvement, features not typically associated with sarcomas, 
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immunohistochemistry for p16 and in situ hybridization for high risk human Papilloma 
virus (HPV) subtypes was performed; this demonstrated that the tumor was, indeed, an 
HPV-driven malignancy compatible with sarcomatoid squamous cell carcinoma. Following 
a course of chemotherapy and radiation therapy, the patient presented two years later with 
deep vein thrombosis and obstructive uropathy, with subsequent biopsy demonstrating 
recurrent metastatic squamous cell carcinoma involving the ureter. 
  
  
Fig. 1. Sarcomatoid squamous cell carcinoma of the vagina. (A) The lesion is characterized 
exclusively by spindled cells, architecturally arranged in fascicles. No in situ or conventional 
squamous cell morphology is apparent [200x original magnification]. (B) High-power 
magnification shows spindled cells with abundant mitotic figures [400x original 
magnification]. (C) Neoplastic cells show diffuse nuclear reactivity for p16, indicative of a 
HPV-driven tumor [400x original magnification]. (D) Chromogenic in situ hybridization for 
high-risk HPV subtypes demonstrates diffuse nuclear chromogenic labeling (in blue dot 
pattern) [400x original magnification]. 
Case number two: 78 year old Para 1 woman with long-standing vulvar irritation presented 
with a 4cm vulvar lesion. She underwent biopsies that demonstrated a high-grade vulvar 
intraepithelial lesion (VIN III, carcinoma in situ), and subsequent wide local excision showed 
involved margins. Four years later, she re-presented with a 4cm, enlarging vulva mass; 
excision of this mass revealed an invasive, poorly differentiated Sarcomatoid Squamous Cell 
Carcinoma (SSCC), again with positive margins. She subsequently underwent a bilateral 
simple hemivulvectomy with pathology demonstrating involvement of the urethral margin, 
1A 1B 
1D 1C 
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with other margins uninvolved. A metastatic evaluation was negative.  Other comorbidities 
rendered the patient to be a poor candidate for additional surgical intervention.  
  
Fig. 2. (A) Sarcomatoid squamous cell carcinoma of the vulva. The lesion has an interface 
with an in situ component (left side of image), and transitions to a tumor of predominant 
spindled cell morphology (right side of image) [100x original magnification]. (B) High-
power magnification shows spindle cell morphology in a fascicular architectural pattern, 
imparting a mesenchymal-like, sarcomatoid morphology [400x original magnification]. 
3. Incidence 
The incidences of SSCC has not been well established but is deemed to be very low from the 
isolated published case reports, constituting, at most only 1-2% of all gynecologic 
malignancies overall. There have been more reported cases of vulvar and cervical SSCC than 
cases from the vagina. This trend is also seen in squamous cell carcinomas of the female 
genital tract, with cervix and vulvar being more common than vagina. In general, SSCC are 
observed in more frequency with advancing age, and there is a correlation between vaginal 
cancers in women who have undergone a hysterectomy for malignant disease. It would be 
interesting to see if this is also true in SSCC. A possibility for the low incidence of SSCC is 
that the sarcomatoid component is under recognized, or under reported as part of the 
pathology report.  
4. Risk factors 
Risk factors for SSCC of the female genital tract are assumed to be the same as risk factors 
for Squamous cell carcinoma. This is even more so if the belief that SSCC transforms from 
SCC. Risk factors include HPV infection, high risk sexual behavior, cigarette smoking, 
specific vitamin deficiencies, and immunosupression. 
Human Papillomavirus (HPV) is a well known causal factor for the development of 
squamous cell carcinoma of the vulva, vagina, cervix, anus, and oropharynx.It is the most 
frequently diagnosed sexually transmitted disease in the United States. HPV subtypes 16 
and 18 in particular have a high known oncogenic potential and are thus called “high 
risk”subtypes, accounting for approximately 80% of cases of invasive cervical cancer. 
(Bereck and Hacker, 2010). HPV has been reported to affect roughly 20 million people in the 
U.S. and is the most frequently diagnosed STD. This number is expected to decrease as more 
2A 2B 
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young 2A 2B Sarcomatoid Squamous Cell Carcinoma 7 women and men are being offered 
the Gardasil and Cervarix injections. These injections are FDA improved and are aimed at 
immunizing against some of the “high risk” human papillomavirus types that predispose to 
cancer and the “low risk” subtypes of human papillomavirus that cause genital warts. 
Despite relatively wide availability, less than 30% of patients receive the recommended 
three doses. (NCI Cancer Bulletin, 2011) Even though the rates of HPV infection decrease 
sharply after 30 years of age, older women are less likely to clear an infection with a high 
risk subtype of HPV. The older the patient at presentation the more likely the patient will 
have a more advanced stage (Berek and Hacker 201 
High risk sexual behavior is a risk factor due to the increase in exposure to sexually 
transmitted infections (STI). The more sexual partners one has the higher the chance that 
they will become infected with an STI. This is partly due to the fact that some STI’s cause 
disruption of the epithelial cell layer that can facilitate the transport of infectious material. 
When the cervix is exposed to infection it undergoes reparative metaplastic changes that can 
also increase susceptibility of and STI. (Bereck and Hacker, 2010) 
Cigarette smokers are known to be at increased risk of cancer of the lungs and other body 
organs including the cervix and vulva. Cigarette smoke is an independent risk factor for 
cervical cancer. (Nishino, K. et al, 2008) The pathogenesis is due to the elevated levels of 
genotoxic breakdown products that are in the cigarettes, including nicotine, cotinine, 
hydrocarbons, and tars, that have mutagenic properties that are present in cervical mucus 
and cells. (Berek and Hacker, 2010) Coker et al (2009) found that smokers were 21% more 
likely to succumb to cervical cancer compared to those who did not smoke at all, suggesting 
that it expedites the disease process due to the inhibited epithelial immune response.  
Although there has been a lack of sound evidence that vitamins and minerals has a clinically 
significant affect on the progression and prevention of cancer (World Cancer Research Fund, 
2007), there have been several studies that have shown a benefit of certain nutrients and 
vitamins. Research continues to find a correlation between essential vitamin and nutrient 
intake and the progression/prevention of breast, cervical, prostate, and colon cancer. 
Vitamins A, C, D, and E have been depicted to have protective properties. Vitamin A has 
some role in regulating differentiation, growth, and apoptosis of normal as well as 
malignant cells. (Cui et al, 2008) The role of Vitamin C has been in the foraging of free 
radicals. Vitamin E works in conjunction with vitamins A and C to regulate cell 
differentiation and proliferation, to scavenge free radicals and oxidants, and may reduce the 
persistence of HPV as well as inhibit cervical carcinogenesis by augmenting immunological 
function and modulating the inflammatory response to infection. (Kim et al, 2010)  Toner 
and Milner (2010) found that even though Vitamin D has been shown to be beneficial in 
cancer prevention the problem lies in finding a standard and most beneficial dosage and 
also showed that there were risk with overexposure.  
There are several disease states that can result in immunosupression. These include HIV, 
transplant patients, cancer patients undergoing chemotherapy, congenital immunodeficiency 
disorders, and immunosuppressive drugs, among others. The main physiological function of 
the immune cells is to monitor tissue homeostasis, to protect against invading pathogens, and 
to eliminate transformed or damaged cells. (Bremmes et al, 2011) When the physiologic 
function of immune cells are interrupted in any way, the body has an impeded response to the 
recognition and response to cancer cells. This delayed response and recognition aides in the 
www.intechopen.com
 Squamous Cell Carcinoma 60
more rapid progression of cancer. Studies on immunotherapy in cancer patients have been 
ongoing and there have been great advances, giving validity that the immune response is an 
important mediator in preventing and fighting off cancer. 
5. Pathogenesis 
There have been many hypotheses about the pathogenesis of SSCC, including the basis of its 
aggressiveness. The theory that is longstanding and the most accepted is that there is a 
transformation from the squamous cell carcinoma component into a spindle cell cancer. This 
is mainly due to parallel immunohistochemical, molecular, and ultrastructural 
characteristics. In 1960, Hay-Roe et al found that the epithelial portion of SSCC of the 
esophagus had an apparent tendency to become spindled in tissue culture. This was also 
reported by Sherwin et al (1963) which also stated there is a probable loss of unity of the 
epithelial cells in the basal layer and this was the major feature causing the spindle cell 
transformation. Raptis et. al (1993) showed a relative decrease in desmosomes and 
tonofilaments within the spindled component therefore lacking the structural foundation of 
ordinary squamous cell carcinoma and might be more susceptible to the compressing effect 
of surrounding stroma. The fact that the spindle cells have desmosomes and tonofilaments 
confirms the squamous cell origin. Lastly, there has been speculation that the spindle cell 
component and the squamous cell component arise concurrently from distinct stem cell 
lines and thus SSCC has been termed a “collision” tumor and not a single tumor with 
conversion to a spindled cell type. (Otay et al. 2011)  
6. Presentation 
The disease process of Sarcomatoid Squamous Cell Carcinoma is very aggressive, patients 
typically present with extensive local disease or with metastasis on imaging and during 
surgery. The clinical signs and symptoms do not correlate to the severity of disease. Early 
nonspecific symptoms can include fatigue, anemia, pelvic pain, pelvic pressure, 
constipation, bloating, weight loss, and loss of appetite.  
The most common presenting symptom of cervical SSCC was abnormal vaginal bleeding.  
There have also been cases of patients complaining of a foul smelling discharge (Brown et al 
2003), postcoital spotting (Kong et al, 2010). In all of the cases of cervical SSCC there was a 
visible cervical lesion ranging from 1.6cm to 10cm. Vaginal lesions can present in a similar 
fashion with vaginal bleeding and a yellowish-white vaginal discharge. On physical exam a 
mass was usually palpable. Vulvar lesions usually present with the patient reporting a 
lesion that bleeds, is expanding, and/or is worrisome. In a small percentage of patients, 
there were no signs or symptoms of a genital mass. SSCC lesions of the cervix, vagina, and 
vulva, were all described similarly in the text as being ulceroproliferative, friable, of 
polypoid configuration, and necrotic in areas. 
7. Diagnosis 
The hallmark of diagnosing this disease is biopsy of the lesion. It is important to get an 
adequate specimen to increase the probability of accurately diagnosing the cancer. There is 
no consensus as to the diameter and depth of specimen that gives the highest yield for 
proper pathological evaluation. 
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An excisional biopsy is one in which the entire mass is removed with a margin of normal 
tissue. This is done in the OR for the most part under sedation or if the lesion is small 
enough in the office with local anesthesia. Since the lesion is friable, supplies for bleeding 
should be readily available. Excisional biopsy is preferred for smaller lesions in which 
margins are available and do not interfere with surrounding structures. An incisional 
biopsy, in which the surgeon removes a portion of the mass, may be done in the office or in 
the operating room. This is utilitized in the event the mass is too large to obtain normal 
margin of surrounding tissue.  
7.1 Histology 
In general, the histopathological diagnosis of SSCC rests upon demonstration of a 
malignancy with regions of classic squamous cell carcinoma morphology, merging with 
those exhibiting a prominent spindle cell component. In cases where such a transition 
occurs, and/or where a squamous cell carcinoma in situ interface is evident, the diagnosis 
can be confidently rendered on morphologic grounds alone.  
However, in situations where the spindled cell component predominates, without areas of 
classic squamous morphology or an interface with an in situ carcinoma component, the 
diagnosis is particularly challenging, as key differential diagnostic considerations would 
include a sarcoma. Such was the case with the current vaginal lesion, which was a tumor 
demonstrating exclusive spindled cell morphology; as immunohistochemistry for muscle 
markers (smooth muscle actin) was positive, the lesion was initially thought to reflect a 
leiomyosarcoma. In review of the cases, some report round to polygonal cells, scanty 
eosinophilic cytoplasm, irregular nuclei, prominent nucleoli, numerous mitosis, and areas of 
necrosis with interlacing bundles of spindle cells on microscopic exam.  
7.2 Immunohistochemical methodologies including HPV detection  
There are many tools in modern immunohistochemistry that may aid in facilitating the 
diagnosis of SSCC, but may also pose significant nuances. In our case of SSCC of the vagina, 
tumor cells which are exclusively spindled in morphology, were positive for markers 
associated with both, mesenchymal and epithelial differentiation, including cytokeratin, 
vimentin, desmin and smooth muscle actin. Indeed, while one report indicates that 
neoplastic cells of SSCC do not show reactivity for smooth muscle actin (C-P, Lin et al. 2006), 
another reports that this marker may be positive in tumor cells. (Brown et al., 2003). In our 
particular case of SSCC from the vagina, the tumor initially thought to reflect a 
leiomyosarcoma, was ultimately demonstrated to harbor high-risk HPV subtypes by in situ 
hybridization, as well as expression of p16, a tumor suppressor protein implicated in the 
HPV tumorigenesis pathway. These latter findings, despite the morphologic appearance of 
the tumor and the ambiguous immunophenotype, permitted a definitive final diagnosis of 
SSCC. 
8. Staging 
Due to the rarity of this cancer, the FIGO staging system that is used for squamous cell 
carcinoma is also used to stage SSCC of the vulva, vagina, and cervix.  
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Stage I Tumor confined to the vulva
 IA Lesions ≤2 cm in size, confined to the vulva or perineum and with stromal 
invasion ≤1.0 mm*, no nodal metastasis
 IB Lesions >2 cm in size or with stromal invasion >1.0 mm*, confined to the 
vulva or perineum, with negative nodes
Stage II Tumor of any size with extension to adjacent perineal structures (1/3 lower 
urethra, 1/3 lower vagina, anus)
Stage III Tumor of any size with or without extension to adjacent perineal structures 
(1/3 lower urethra, 1/3 lower vagina, anus) with positive inguino-femoral 
lymph nodes
 IIIA i. With 1 lymph node metastasis (≥5 mm), or
ii. 1-2 lymph node metastasis(es) (<5 mm)
 IIIB i. With 2 or more lymph node metastases (≥5 mm), or
ii. 3 or more lymph node metastases (<5 mm)
 IIIC With positive nodes with extracapsular spread
Stage IV Tumor invades other regional (2/3 upper urethra, 2/3 upper vagina), or 
distant structures
 IVA Tumor invades any of the following:
i. upper urethral and/or vaginal mucosa, bladder mucosa, rectal mucosa, 
or fixed to pelvic bone, or 
ii. fixed or ulcerated inguino-femoral lymph nodes
 IVB Any distant metastasis including pelvic lymph nodes
*The depth of invasion is defined as the measurement of the tumor from the epithelial-stromal junction 
of the adjacent most superficial dermal papilla to the deepest point of invasion. (FIGO Committee on 
Gynecologic Oncology. 2009) 
Table 4. Carcinoma of the Vulva FIGO Staging. (2008) 
Stage I The carcinoma is limited to the vaginal wall
Stage II The carcinoma has involved the subvaginal tissue but has not extended to 
the pelvic wall
Stage III The carcinoma has extended to the pelvic wall 
Stage IV The carcinoma has extended beyond the true pelvis or has involved the 
mucosa of the bladder or rectum; bullous edema as such does not permit a 
case to be allotted to stage IV
 IVA Tumor invades bladder and/or rectal mucosa and/or direct extension 
beyond the true pelvis 
 IVB Spread to distant organs 
(FIGO Annual Report. 2006) 
Table 5. Carcinoma of the Vagina FIGO Nomenclature 
Cervical cancer is still staged clinically, which is not always very accurate in portraying the 
extent of the disease. Clinical staging can include palpation, inspection, colposcopy, 
endocervical curettage, hysteroscopy, cystoscopy, proctoscopy, intravenous urography, and 
e-ray examination of the lungs and skeletal system. (Berek and Hacker, 2010) CT and MRI 
are also utilized often as this can give a better idea of extent of disease, margins, 
lymphadenopathy, and other organ involvement. Positron emission tomography (PET) is 
mainly utilized for nodal status. 
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Stage I The carcinoma is strictly confined to the cervix (extension to the corpus 
would be disregarded) 
 IA 
 
        IA1 
 
        IA2 
Invasive carcinoma which can be diagnosed only by microscopy, with 
deepest invasion ≤5 mm and largest extension ≤7 mm 
Measured stromal invasion of ≤3.0 mm in depth and extension of ≤7.0 mm 
Measured stromal invasion of >3.0 mm and not >5.0 mm with an extension 
of not >7 mm 
 IB 
 
        IB1 
        IB2 
Clinically visible lesions limited to the cervix uteri or pre-clinical cancers 
greater than stage IA* 
Clinically visible lesion ≤4.0 cm in greatest dimension 
Clinically visible lesion >4.0 cm in greatest dimension 
Stage II Cervical carcinoma invades beyond the uterus, but not to the pelvic wall or 
to the lower third of the vagina 
 IIA 
        IIA1 
        IIA2 
Without parametrial invasion
Clinically visible lesion ≤4.0 cm in greatest dimension 
Clinically visible lesion >4.0 cm in greatest dimension 
 IIB With obvious parametrial invasion
Stage III The tumor extends to the pelvic wall and/or involves lower third of the vagina 
and/or causes hydronephrosis or non-functioning kidney** 
 IIIA Tumor involves lower third of vagina, with no extension to the pelvic 
sidewall 
 IIIB Extension to the pelvic wall and/or hydronephrosis or non-functioning kidney 
Stage IV The carcinoma has extended beyond the true pelvis or has involved (biopsy 
proven) the mucosa of the bladder or rectum. A bullous edema, as such, does 
not permit a case to be allotted to Stage IV 
 IVA Spread of the growth to adjacent organs
 IVB Spread to distant organs
*All macroscopically visible lesions-even with superficial invasion-are allotted to stage IB carcinomas. Invasion is 
limited to a measured stromal invasion with a maximal depth of 5.00 mm and a horizontal extension of not >7.00 
mm. Depth of invasion should not be >5.00 mm taken from the base of the epithelium of the original tissue-squamous 
or glandular. The depth of invasion should always be reported in mm, even in those cases with “early (minimal) 
stromal invasion” (~1 mm). the involvement of vascular/lymphatic spaces should not change the stage allotment) 
**On rectal examination, there is no cancer-free space between the tumor and the pelvic wall. All cases with 
hydronephrosis or non-functioning kidney are included, unless they are known to be due to another cause.  
(FIGO Committee on Gynecologic Oncology. 2009) 
Table 6. Carcinoma of the Cervix Uteri (2008) 
9. Therapy 
The rarity of these malignancies makes recommendations for standard treatments a 
formidable endeavor. In general, the stage of the cancer will dictate therapy.  
In early stage disease of the vulva, vagina and cervix the role for surgery is more clearly 
defined. These lesions are usually treated with radical surgery followed by radiation 
therapy and/or chemotherapy in certain cases. Size, margin status, and local tumor biology 
might dictate the need for radiotherapy. Brown et al (2003) treated all Stage I and Stage II 
women with radiation therapy alone and this was successfully able to eradicate the tumor. 
This proves radiation to be an effective treatment option, even though some believe it to be a 
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source of the transition of this cancer from SCC to the intermingling of the spindle shaped 
cells. In 2010, Kong et al reported a case of IB1 SSCC of the cervix in a young patient, being 
treated by laparoscopic radical hysterectomy, bilateral pelvic lymph node biopsy, peritoneal 
washing cytology and transposition of both ovaries without adjuvant therapy. Despite the 
initial treatment for low stage cancers, recurrent cancer did not respond to second line 
therapy (Brown et al, 2003) which leads some to take a more aggressive approach with 
surgery and adjuvant therapy, especially since time from recurrence to death is less than a 
year as reported in the literature.   
In more advanced stages, patients present with such extensive disease that surgery is 
usually done on a palliative basis if indicated. These tumors are usually treated with 
concurrent chemotherapy and radiation, extrapolating from the pure squamous 
counterparts. In contradiction to these lesions where there exist more robust standard 
treatment recommendations the response to similar treatment is largely unknown and the 
risk for recurrence is very significant with a very short disease free interval.  
10. Prognosis 
Prognosis of SSCC is very poor. It is a very aggressive cancer, is usually diagnosed at a later 
stage, and most recur within one year despite aggressive combined therapy. As with the 
majority of solid tumors, the survival of patients that were detected at early stages is very 
reassuring. Patients who are diagnosed at Stage I have a higher survival rate at 5 years, 
approaching 90%. In contrast, those who present at Stage IV, according to the studies, have a 
survival rate of less than 5% at five years, according to the review of the case reports. 
Prognostic factors have not been uniformed in any of the studies.  Lane believed the extent of 
the grossly carcinomatous element was the best predictor of survival. Friedel et al found that 
not only was the degree of differentiation of the carcinomatous component an important 
prognostic factor but also the extent of invasiveness. Some suggest size and location are the 
sole factors impacting prognosis. (Randall et al.) Brown et al found that the younger patients 
tended to present at an earlier stage. Of these women who presented at stage 1, all were free of 
disease with the longest interval reported at 42 months. They also found that all patients less 
than 40 presented at Stage I and not a more advanced stage III or IV. One explanation for the 
fact that younger patients present at a lesser stage is that they are more prone to go to the 
doctors for acute visits and are more likely to voice there concerns over abnormal changes in 
their bodies. This is different to the belief that women >40 are more apt to cope with the 
symptoms and only present when the condition is debilitating or they are urged by family.  
11. Conclusion 
SSCC is a very rare cancer that has an aggressive and rapidly fatal course. Due to its rarity, 
there is no distinct staging or guidelines to direct therapy and care. As more cases become 
available and follow up is documented on patients with early FIGO stages, treatments, and 
surveillance decisions there will be a better chance of developing a set of guidelines based 
on the evidence.  Since this cancer is most accepted as being a variant of SCC, the FIGO 
staging and treatment guidelines for squamous cell carcinoma are also used for SSCC. 
Human papillomavirus has been implicated in SCC and is also found in the spindle cell 
component of SSCC. Even with the use of the widely available HPV vaccine and better 
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screening modalities, it is difficult to discern which squamous cell cancers will transition to 
SSCC so no risk prevention can be done. One would assume that with the reduction in 
squamous cell carcinoma cases of the female genital tract that there will be a parallel 
reduction of SSCC. 
Diagnosis has traditionally been difficult due to the large ratio of sarcomatous to squamous 
cell component. Immunohistochemistry and ancillary testing, such as in situ hybridization 
for high-risk HPV subtypes are very important for the precise diagnosis which can guide 
treatment and counseling of the patient. One should perform immunohistochemistry for 
squamous epithelial markers as well as in situ hybridization for HPV when encountering a 
sarcomatoid neoplasm to rule out SSCC.   
As with any cancer, the lower the FIGO stage at diagnosis the better the prognosis. 
Unfortunately even when adequately treated according to unset standards, recurrence is 
very prevalent with disease free interval to death being very rapid. Once recurrence occurs 
there is very little recourse as the cancer does not respond to second line therapy and has 
usually extended out of the pelvis to distant organs. There have been few cases of a FIGO 
stage greater than II in which there has been long term survival but not enough to 
effectively alter the inevitable outcome.  
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